Related Experiment Video
Updated: May 2, 2026
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
3.2K
[Venous thromboembolism and cancer]
1Université Paris-Descartes, Sorbonne Paris-Cité, 75006 Paris, France; Service de pneumologie, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France.
Revue De Pneumologie Clinique
|February 26, 2014
Summary
Patients with cancer have a high risk of venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is effective for VTE in cancer patients but recurrence risk remains high, requiring further research.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Context:
- Venous thromboembolism (VTE) is a significant complication in cancer patients, with incidence varying by cancer type, stage, and treatment.
- Established VTE in cancer patients carries high risks of recurrence and bleeding.
- Current long-term prophylaxis strategies for VTE in cancer lack convincing evidence.
Purpose:
- To review the challenges and current understanding of venous thromboembolism (VTE) management in cancer patients.
- To discuss the efficacy and limitations of low molecular weight heparin (LMWH) compared to vitamin K antagonists for VTE in cancer.
- To highlight ongoing debates regarding extended anticoagulant treatment duration and management of recurrent VTE during anticoagulation.
Summary:
- Low molecular weight heparin (LMWH) demonstrates greater efficiency than vitamin K antagonists for VTE in cancer patients but is associated with a higher recurrence rate than in non-cancer individuals.
- Optimal duration of anticoagulant therapy beyond six months and strategies for managing recurrent VTE during anticoagulation remain subjects of debate.
- Emerging data suggest a potential adjuvant anticancer role for LMWH, though clinical trials are pending confirmation.
Impact:
- Informs clinical decision-making for VTE management in oncology.
- Identifies critical areas for future research in cancer-associated thrombosis.
- Highlights the potential for LMWH to serve dual roles in VTE treatment and possibly as an anticancer agent.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
01:29Pulmonary Embolism I: Introduction
1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
01:19Pulmonary Embolism I: Introduction
39
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
39